NK cells beat T cells at early breast cancer control

Aitziber Buque; Norma Bloy; Giulia Petroni; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2020.1806010

NK cells beat T cells at early breast cancer control

Oncoimmunology. 2020 Aug 23;9(1):1806010. doi: 10.1080/2162402X.2020.1806010.

Authors

Aitziber Buque¹, Norma Bloy¹, Giulia Petroni¹, Guido Kroemer^{2

3

4

5

6}, Lorenzo Galluzzi^{1

7

8

9

10}

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Equipe Labellisée Par la Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
³ Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
⁴ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
⁵ Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
⁶ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
⁷ Sandra and Edward Meyer Cancer Center, New York, NY, USA.
⁸ Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.
⁹ Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
¹⁰ Université de Paris, Paris, France.

Abstract

Cancer immunosurveillance generally relies on adaptive immune programs executed by CD8⁺ T cells. Our findings demonstrate that CD8⁺ T cells fail to control early oncogenesis in a mouse model of luminal B breast cancer and suggest that natural killer (NK) cells may instead play a predominant role in this setting.

Keywords: Hormonotherapy; PD-1; immune checkpoint blockers; nicotinamide; tumor microenvironment; type I interferon.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Animals
CD8-Positive T-Lymphocytes*
Killer Cells, Natural
Mice
Neoplasms*